Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study

Yen Hou Chang, Chien Hsing Lu, Ming Shyen Yen, Wai Hou Lee, Yi Chang, Wei Pin Chang, Chi Mu Chuang

Research output: Contribution to journalLetter

Abstract

We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

Original languageEnglish
Article number45
JournalChinese Journal of Cancer
Volume35
Issue number5
DOIs
Publication statusPublished - May 1 2016
Externally publishedYes

Fingerprint

Propensity Score
Paclitaxel
Cohort Studies
Survival
Residual Neoplasm
Cisplatin
Neoplasms
Appointments and Schedules
Prospective Studies
Drug Therapy

Keywords

  • Clinical trials
  • Epithelial ovarian, tubal, and peritoneal cancer
  • Intraperitoneal chemotherapy
  • Propensity score
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study. / Chang, Yen Hou; Lu, Chien Hsing; Yen, Ming Shyen; Lee, Wai Hou; Chang, Yi; Chang, Wei Pin; Chuang, Chi Mu.

In: Chinese Journal of Cancer, Vol. 35, No. 5, 45, 01.05.2016.

Research output: Contribution to journalLetter

Chang, Yen Hou ; Lu, Chien Hsing ; Yen, Ming Shyen ; Lee, Wai Hou ; Chang, Yi ; Chang, Wei Pin ; Chuang, Chi Mu. / Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study. In: Chinese Journal of Cancer. 2016 ; Vol. 35, No. 5.
@article{044f1ab73bb44d7287fb5e6460496fab,
title = "Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study",
abstract = "We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.",
keywords = "Clinical trials, Epithelial ovarian, tubal, and peritoneal cancer, Intraperitoneal chemotherapy, Propensity score, Survival",
author = "Chang, {Yen Hou} and Lu, {Chien Hsing} and Yen, {Ming Shyen} and Lee, {Wai Hou} and Yi Chang and Chang, {Wei Pin} and Chuang, {Chi Mu}",
year = "2016",
month = "5",
day = "1",
doi = "10.1186/s40880-016-0105-3",
language = "English",
volume = "35",
journal = "Cancer Communications",
issn = "1000-467X",
publisher = "BioMed Central Ltd.",
number = "5",

}

TY - JOUR

T1 - Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study

AU - Chang, Yen Hou

AU - Lu, Chien Hsing

AU - Yen, Ming Shyen

AU - Lee, Wai Hou

AU - Chang, Yi

AU - Chang, Wei Pin

AU - Chuang, Chi Mu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

AB - We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

KW - Clinical trials

KW - Epithelial ovarian, tubal, and peritoneal cancer

KW - Intraperitoneal chemotherapy

KW - Propensity score

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84970024061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970024061&partnerID=8YFLogxK

U2 - 10.1186/s40880-016-0105-3

DO - 10.1186/s40880-016-0105-3

M3 - Letter

VL - 35

JO - Cancer Communications

JF - Cancer Communications

SN - 1000-467X

IS - 5

M1 - 45

ER -